Clinical trial
Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
NCT04638309 is registered in ClinicalTrials.gov with Aprea Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Study to Evaluate Safety and Efficacy of APR-548 in Combination With Azacitidine for the Treatment of TP53-Mutant Myelodysplastic Syndromes
- Lead sponsor
- Aprea Therapeutics
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- September 20, 2021
- Completion date
- April 25, 2022
- Enrollment
- 4 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.